Recent insider trends for Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) have caught the attention of investors. Insider data is useful because it can reveal what a company’s executives and largest shareholders feel about a stock. In this case, the data has some interesting things to say about how IDRA might perform in the future.
Institutions own 31.18% of Idera Pharmaceuticals, Inc. (IDRA)’s shares. The total value of these holdings, in millions, is $91. Among active positions in the latest quarter, 37 holders increased their positions by a total of 2.78 million shares, 34 holders decreased the positions by a total of 3.08 million shares, and 22 holders held their positions. This works out to a net decrease in ownership of 299640 shares, and suggests that institutions are feeling bearish about the stock.
Among new and sold out positions, 9 holders initiated new positions by a total of 1.58 million shares and 10 holders exited their positions by a total of 828215 shares. This nets out to an increase of 754301 shares and is a bullish sign for IDRA.
In the last three months, insiders executed a total of 3 trades. 3 of these were buys and 0 were sells. Insider ownership increased by a total of 49226 shares, which suggests that IDRA’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: insiders executed 12 buys and 3 sells, and ownership increased by a net of 1.64 million shares.
Analysts often look at short interest, or the number of shares currently being shorted by investors, to aid in their outlook for a particular stock. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)’s short interest is 11.98 million shares, or 8.74% of the float. This represents a decrease of -2% in the number of shares being shorted compared to the previous reading, and implies that investors felt less pessimistic about the stock during the past two weeks.
Ownership trends and trading patterns can be useful tools for predicting a stock’s performance, but it’s also important to consider the technicals in order to form a more comprehensive view. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that IDRA is a buy, which implies that IDRA is expected to outperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) is undervalued.